Stockreport

Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations

Gilead Sciences, Inc.  (GILD) 
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
PDF BOSTON--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented longer-term results from the DISCOVER trial of Descovy (emtricitabine 200 mg and tenofo [Read more]